Frequency of Common Gene Mutations
Seventy-five patients (median age 68 years, range 38-95; 35 men and 40 women) underwent CGP testing between November 2015 and October 2017. The majority of cancer types were breast, pancreatic, prostate, colon, and non-small cell lung. Most common DNA mutations recorded were TP53, PTEN, PI3KCA, and BRAF. There was a median of 3 mutations/patient (range 0-11), with a 0% sample failure rate. Overall, 10 cases had no detectable mutations (13.3%). There were six samples with PD-L1 results, and one was positive (16.7%), in the range of expected PD-L1 positivity across solid tumors. In addition to the 10 mutation negative cases, 3 cases had no potential match for CA or CT (e.g. APC, NOTCH1, SMAD4 mutations). Thus, 62 (82.7%) of cases had the potential for CA and/or CT drug identified by liquid biopsy (Table I ). All samples were run within 5 days of collection. Median TAT was 7 days. Comparing 2015 to 2017 TAT results, the TAT significantly improved from a median of 12 days to a median of 6 days, respectively (p=0.0005). CGP is priced at approximately $600 per sample comparable to current reimbursement rate.
This analysis indicates that CGP has a high probability for identifying a potential CA or CT for a stage 4 solid tumor patient with a rapid TAT and markedly lower cost than any other commercially available NGS assays. In this real world experience, despite the low plasma sample input, there were no sample failures, suggesting CGP in situ enrichment is robust. More experience with this assay and linkage with clinical outcomes is warranted. 
RESULTS

CONCLUSIONS
Circulogene's focus is here. Other extraction methods (silica matrix-based isolation) have 70-80% material loss.
Other liquid biopsy assays focus efforts here.
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DNA mutations detected and, where available, PD-L1 expression, ALK, and ROS1 fusions in RNA were retrospectively compiled from CGP ordered at a single center. To be considered clinically actionable and commercially available (CA), the biomarker had to have demonstrated clinical efficacy in human cancer prospective trials using the biomarker and commercially available drug that can target that biomarker. To be considered a clinical trial possibility (CT), one of the biomarkers was required to have a drug in clinical development using the biomarker for the patient's cancer type listing on clinicaltrials. gov during the time period that CGP was ordered. Turnaround time (TAT) was calculated as the difference in calendar days between the date the sample was received at the vendor to the date of the first NGS report for that sample. A Student's t-test was applied to TAT calculations.
